Prime Medicine, Inc. (PRME) Market Cap & Valuation Ratios
Prime Medicine, Inc. (PRME) has a market cap of $665.7M and a price-to-sales ratio of 163.4, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PRMEPrime Medicine, Inc.Follow PRME — free
—
Price chart with a free account
- Market cap
- 665.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| PRME | 0.7 | — | 140.1 | — | — | -18% | — | — |
| GERN | 0.7 | — | — | — | — | — | — | -18% |
| SANA | 0.7 | — | — | — | — | — | — | -294% |
| OABI | 0.7 | — | 16.3 | — | -2.7% | +67% | -126% | -20% |
| DNA | 0.7 | — | 5.3 | — | — | -52% | -260% | -78% |
| ACHV | 0.7 | — | — | — | -7.4% | — | — | — |
| AURA | 0.7 | — | — | — | — | — | — | -88% |
| DSGN | 0.6 | — | — | — | -8.6% | — | — | -42% |
| SLDB | 0.6 | — | — | — | — | — | — | -127% |
| LXRX | 0.6 | — | 11.9 | — | -10.3% | -29% | -131% | -30% |
| WVE | 0.6 | — | 4.0 | — | — | -30% | -333% | -255% |
| Median of these 10 | — | 8.6 | — | -8.0% | -30% | -196% | -78% |
; EV/Sales 140.1 vs. 8.6.
Growth vs. price
each dot a company · hover or tap for valuesPrime Medicine, Inc. — questions
- What is Prime Medicine, Inc.'s market cap?
- $665.7M.
- What is Prime Medicine, Inc.'s price-to-sales ratio?
- 163.4.
Every figure on this page comes from Prime Medicine, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.